课件：分子靶向治疗在淋巴瘤中的应用.ppt

* Actuarial survival curves for patients with indolent NHL treated at Stanford University from 1960 to 1976, 1976 to 1987, and 1987 to 1996 are essentially indistinguishable, which shows that the widespread use of single-agent or multiagent chemotherapy or combined modality therapy has not had a significant impact on the natural course of the disease.54 * There is now a considerable body of evidence demonstrating a significant clinical benefit with rituximab maintenance therapy in follicular lymphoma (FL). These studies have demonstrated a benefit for rituximab maintenance in previously untreated, relapsed and refractory FL and after induction with rituximab monotherapy and rituximab-containing immunochemotherapy. * 瑞士癌症研究组SAKK开展这个随机临床旨在评估利妥昔单抗维持与观察比较对于滤泡性淋巴瘤的长期疗效 * * 2 2 We kno from basic studies in the early 80′s, that 2-CdA is inducing apoptosos in dividing but also in resting cells independent from cell cycle. This observation lead to the idea, that this could be an advantage in the therapy of indolent lymphomas. It is well known that 2-CdA is very effective in the treatment of HCL, inducing very long lasting complete remissions. But 2-Cda has also been demonstrated to be effective in other indolent lymphoproliferative disorders like low-grade NHL, CLL and cutaneous lymphomas and also in relapsed ALL. It was in 1992, that the Group from the Scripps-Clinic in San Diego, and in 1995 also Liliemark and Juliusson demonstrated the efficacy of cladribine in pretreated patients with NHL. However, in these heavily pretreated patients a high rate of severe infectious problems was reported in the range of about 20-40%, probably due to the extensive pretreatment. In 1995, again Saven and Piro from the Scripps Clinic, demonstrated the activity of Cladribine for the first time in untreated indolent NHL. They used the 7-day continous infusion regimen with 0,1 mg/kg/d, which is the approved schedule in the USA using 2-CdA. * 针对CD22抗原的抗体：SM03, Epratuzumab(已完成I/II期临床试验，进入II